Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $72.50 price target on CRISPR Therapeutics (NASDAQ: CRSP) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

CRISPR Therapeutics (CRSP) Gains on ChatterOctober 28, 2019 10:16 AM Form 10-Q CRISPR Therapeutics AG For: Sep 30October 28, 2019 8:02 AM Form 8-K CRISPR Therapeutics AG For: Oct 28October 28, 2019 7:06 AM CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial ResultsOctober 28, 2019 7:00 AM